½ÃÀ庸°í¼­
»óǰÄÚµå
1618647

¸¶¿ì½º ¸ðµ¨ ½ÃÀå : À¯Çüº°, ±â¼úº°, Ä¡·á ºÐ¾ßº°, ¿ëµµº° - ¼¼°è ¿¹Ãø(2025-2030³â)

Mice Model Market by Type (Conditioned/Surgically Modified Mice, Genetically Engineered Mice, Hybrid/Congenic Mice), Technology (CRISPR/CAS9, Embryonic Stem Cell Injection, Microinjection), Therapeutic Area, Application - Global Forecast 2025-2030

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: 360iResearch | ÆäÀÌÁö Á¤º¸: ¿µ¹® 186 Pages | ¹è¼Û¾È³» : 1-2ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡á º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼ÛÀÏÁ¤Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

¸¶¿ì½º ¸ðµ¨ ½ÃÀåÀº 2023³â 14¾ï 9,000¸¸ ´Þ·¯·Î Æò°¡µÇ¸ç 2024³â¿¡´Â 16¾ï 1,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, ¿¬Æò±Õ 8.34% ¼ºÀåÇÏ¿© 2030³â¿¡´Â 26¾ï 1,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¸¶¿ì½º ¸ðµ¨ ½ÃÀåÀº »ý¹° ÀÇÇÐ ¿¬±¸¿¡¼­ À¯ÀüÀÚ Á¶ÀÛ ¸¶¿ì½ºÀÇ »ç¿ëÀ» Æ÷°ýÇϸç, Àΰ£ Áúº´ ÀÌÇØ, ÀǾàǰ °³¹ß ¹× Ä¡·á ½ÃÇèÀ» À§ÇÑ ÇʼöÀûÀÎ µµ±¸·Î¼­ ±¤¹üÀ§ÇÑ ¹üÀ§¸¦ Á¦°øÇÕ´Ï´Ù. ÀÌ·¯ÇÑ ¸ðµ¨Àº Àΰ£°ú À¯ÀüÀûÀ¸·Î À¯»çÇϱ⠶§¹®¿¡ ¸Å¿ì Áß¿äÇϸç, ¾Ï, ½ÉÇ÷°üÁúȯ, ´ë»ç¼º Áúȯ µî¿¡ ´ëÇÑ ÀλçÀÌÆ®¸¦ ½±°Ô ¾òÀ» ¼ö ÀÖ½À´Ï´Ù. ¸¶¿ì½º ¸ðµ¨ÀÇ Çʿ伺Àº Àΰ£ Áúº´ Ç¥ÇöÇüÀ» ¸ðµ¨¸µÇÒ ¼ö ÀÖ´Â ´É·ÂÀ¸·Î ÀÎÇØ °­Á¶µÇ°í ÀÖÀ¸¸ç, ±× °á°ú Áß°³ ¿¬±¸ ¹× ÀüÀÓ»ó ¿¬±¸¿¡ ¸Å¿ì À¯¿ëÇÏ°Ô È°¿ëµÇ°í ÀÖ½À´Ï´Ù. ¿ëµµº°·Î´Â Á¦¾à, »ý¸í°øÇÐ, Çмú ¿¬±¸±â°ü µî¿¡¼­ äÅÃÇϰí ÀÖÀ¸¸ç, ÃÖÁ¾»ç¿ëÀÚ ¹üÀ§´Â ½Å¾à°³¹ß, µ¶¼ºÇÐ, À¯ÀüÀÚ ¿¬±¸ µî ´Ù¾çÇÕ´Ï´Ù. À¯Àüü ¿¬±¸¿¡ ´ëÇÑ Á¤ºÎ ÀÚ±Ý Áö¿ø Áõ°¡, ¸ÂÃãÇü ÀÇ·á¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡, CRISPR ¹× ±âŸ À¯Àü°øÇÐ ±â¼úÀÇ ¹ßÀüÀÌ ÀÌ ½ÃÀåÀÇ ¼ºÀåÀ» ÁÖµµÇϰí ÀÖ½À´Ï´Ù. ¸¸¼ºÁúȯÀÇ ±ÞÁõÀ¸·Î È¿À²ÀûÀÎ µ¿¹° ¸ðµ¨ÀÇ Çʿ伺µµ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ±×·¯³ª µ¿¹° ½ÇÇè¿¡ ´ëÇÑ À±¸®Àû ¿ì·Á¿Í ¾ö°ÝÇÑ ±ÔÁ¦ ÇÁ·¹ÀÓ¿öÅ©´Â Å« µµÀüÀÌ µÇ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, À¯Àü°øÇÐ ¸ðµ¨ °³¹ß¿¡ µû¸¥ º¹À⼺°ú ³ôÀº À¯Áöºñ¿ëÀº ½ÃÀå °³Ã´¿¡ °É¸²µ¹ÀÌ µÉ ¼ö ÀÖ½À´Ï´Ù. ±âȸ´Â º¸´Ù Á¤±³ÇÑ Àΰ£È­ ¸¶¿ì½º ¸ðµ¨ °³¹ß°ú º¸´Ù Á¤È®ÇÑ µ¥ÀÌÅÍ ¼öÁýÀ» À§ÇÑ ¿µ»ó Áø´Ü ¹× ¸ð´ÏÅ͸µ ±â¼ú °­È­¿¡ ÀÖ½À´Ï´Ù. µ¥ÀÌÅÍ °øÀ¯¸¦ À§ÇÑ ¿ÀÇ ¾×¼¼½º Ç÷§ÆûÀ» äÅÃÇÏ¸é º¸´Ù ±¤¹üÀ§ÇÑ °øµ¿ ¿¬±¸¸¦ ÃËÁøÇϰí ÁøÀüÀ» °¡¼ÓÈ­ÇÒ ¼ö ÀÖ½À´Ï´Ù. ºñħ½ÀÀû À̹Ì¡ ±â¼ú°ú µðÁöÅÐ º´¸®ÇÐÀÇ Çõ½ÅÀº ¿¬±¸ °³¹ßÀÇ À¯·ÂÇÑ ºÐ¾ßÀÔ´Ï´Ù. ½ÃÀå ¿ªÇÐÀº ¸Å¿ì ¿ªµ¿ÀûÀÌ°í °æÀïÀÌ Ä¡¿­Çϸç, ¸ðµ¨ Á¤È®µµ¸¦ ³ôÀ̰í À±¸®Àû ¿ì·Á¸¦ ¿ÏÈ­ÇÏ´Â ±â¼ú Çõ½ÅÀÌ Ç×»ó °­Á¶µÇ°í ÀÖ½À´Ï´Ù. ±â¾÷µéÀº AI¸¦ Ȱ¿ëÇÑ µ¥ÀÌÅÍ ºÐ¼®°ú °°Àº »õ·Î¿î Æ®·»µå¿Í ÀÓ»ó ¿¬±¸ ÀÎÇÁ¶ó°¡ ¼ºÀåÇϰí ÀÖ´Â ¹Ì°³Ã´ Áö¿ªÀ¸·Î ÁøÃâÇÏ´Â °ÍÀÌ Å« ¼ºÀåÀ» °¡Á®¿Ã ¼ö ÀÖ½À´Ï´Ù. Àü¹ÝÀûÀ¸·Î ½ÃÀåÀº µµÀü°úÁ¦¿¡ Á÷¸éÇØ ÀÖÀ¸¸ç, È¿À²ÀûÀÎ ¿¬±¸ ¸ðµ¨¿¡ ´ëÇÑ Áö¼ÓÀûÀÎ ¼ö¿ä´Â °­·ÂÇÑ ¼ºÀå ÀáÀç·ÂÀ» °¡Áö°í ÀÖ½À´Ï´Ù.

ÁÖ¿ä ½ÃÀå Åë°è
±âÁØ ¿¬µµ[2023] 14¾ï 9,000¸¸ ´Þ·¯
¿¹Ãø ¿¬µµ[2024] 16¾ï 1,000¸¸ ´Þ·¯
¿¹Ãø ¿¬µµ[2030] 26¾ï 1,000¸¸ ´Þ·¯
CAGR(%) 8.34%

½ÃÀå ¿ªÇÐ : ºü¸£°Ô ÁøÈ­ÇÏ´Â ¸¶¿ì½º ¸ðµ¨ ½ÃÀåÀÇ ÁÖ¿ä ½ÃÀå ÀλçÀÌÆ® °ø°³

¸¶¿ì½º ¸ðµ¨ ½ÃÀåÀº ¼ö¿ä¿Í °ø±ÞÀÇ ¿ªµ¿ÀûÀÎ »óÈ£ÀÛ¿ëÀ» ÅëÇØ º¯È­Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ½ÃÀå ¿ªÇÐÀÇ ÁøÈ­¸¦ ÀÌÇØÇÔÀ¸·Î½á ±â¾÷Àº Á¤º¸¿¡ ÀÔ°¢ÇÑ ÅõÀÚ °áÁ¤, Àü·«Àû ÀÇ»ç°áÁ¤, »õ·Î¿î ºñÁî´Ï½º ±âȸ¸¦ Æ÷ÂøÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Æ®·»µå¸¦ Á¾ÇÕÀûÀ¸·Î ÆÄ¾ÇÇÔÀ¸·Î½á ±â¾÷Àº Á¤Ä¡Àû, Áö¸®Àû, ±â¼úÀû, »çȸÀû, °æÁ¦Àû ¿µ¿ª Àü¹Ý¿¡ °ÉÄ£ ´Ù¾çÇÑ ¸®½ºÅ©¸¦ ÁÙÀÏ ¼ö ÀÖÀ¸¸ç, ¼ÒºñÀÚ Çൿ°ú ±×°ÍÀÌ Á¦Á¶ ºñ¿ë ¹× ±¸¸Å µ¿Çâ¿¡ ¹ÌÄ¡´Â ¿µÇâÀ» º¸´Ù ¸íÈ®ÇÏ°Ô ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù.

  • ½ÃÀå ÃËÁø¿äÀÎ
    • ¾à¹°½ÃÇè ¹× ¸é¿ªÁúȯ ¿¬±¸¿¡ ¸¶¿ì½º ¸ðµ¨ Ȱ¿ë È®´ë
    • ÀǾàǰ ¿¬±¸°³¹ß Ȱµ¿ÀÇ ±ÞÁõ¿¡ µû¸¥ ÅõÀÚ ¹× º¸Á¶±Ý Áõ°¡
  • ½ÃÀå ¾ïÁ¦¿äÀÎ
    • ¸¶¿ì½º ¸ðµ¨ °³¹ß¿¡ µû¸¥ °íºñ¿ë
  • ½ÃÀå ±âȸ
    • ¸¶¿ì½º ¸ðµ¨¸µ¿¡¼­ AI¿Í ML µµÀÔÀÇ ºÎ»ó
    • ¸¶¿ì½º ¸ðµ¨ Á¦ÀÛ¿¡ ÀÖ¾î CRISPR-Cas9 ±â¼úÀÇ µîÀå
  • ½ÃÀå °úÁ¦
    • ¿¬±¸¿¡¼­ µ¿¹°ÀÇ À±¸®Àû »ç¿ëÀ» °í·ÁÇÑ ¾ö°ÝÇÑ ±ÔÁ¦¿Í ¹ý±Ô

Porter's Five Forces : ¸¶¿ì½º ¸ðµ¨ ½ÃÀå °ø·«À» À§ÇÑ Àü·« µµ±¸

Porter's Five Forces ÇÁ·¹ÀÓ¿öÅ©´Â ½ÃÀå »óȲÀÇ °æÀï »óȲÀ» ÀÌÇØÇÏ´Â Áß¿äÇÑ µµ±¸ÀÔ´Ï´Ù. Porter's Five Forces ÇÁ·¹ÀÓ¿öÅ©´Â ±â¾÷ÀÇ °æÀï·ÂÀ» Æò°¡Çϰí Àü·«Àû ±âȸ¸¦ Ž»öÇÒ ¼ö ÀÖ´Â ¸íÈ®ÇÑ ¹æ¹ýÀ» Á¦°øÇÕ´Ï´Ù. ÀÌ ÇÁ·¹ÀÓ¿öÅ©´Â ±â¾÷ÀÌ ½ÃÀå ³» ¼¼·Âµµ¸¦ Æò°¡ÇÏ°í ½Å±Ô »ç¾÷ÀÇ ¼öÀͼºÀ» ÆÇ´ÜÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ÀÌ·¯ÇÑ ÀλçÀÌÆ®¸¦ ÅëÇØ ±â¾÷Àº °­Á¡À» Ȱ¿ëÇϰí, ¾àÁ¡À» ÇØ°áÇϰí, ÀáÀçÀûÀÎ µµÀüÀ» ÇÇÇϰí, º¸´Ù °­·ÂÇÑ ½ÃÀå Æ÷Áö¼Å´×À» È®º¸ÇÒ ¼ö ÀÖ½À´Ï´Ù.

PESTLE ºÐ¼® : ¸¶¿ì½º ¸ðµ¨ ½ÃÀå¿¡¼­ÀÇ ¿ÜºÎ ¿µÇâ ÆÄ¾Ç

¿ÜºÎ °Å½Ã ȯ°æ ¿äÀÎÀº ¸¶¿ì½º ¸ðµ¨ ½ÃÀåÀÇ ¼º°ú ¿ªÇÐÀ» Çü¼ºÇÏ´Â µ¥ ¸Å¿ì Áß¿äÇÑ ¿ªÇÒÀ» ÇÕ´Ï´Ù. Á¤Ä¡Àû, °æÁ¦Àû, »çȸÀû, ±â¼úÀû, ¹ýÀû, ȯ°æÀû ¿äÀο¡ ´ëÇÑ ºÐ¼®Àº ÀÌ·¯ÇÑ ¿µÇâÀ» Ž»öÇÏ´Â µ¥ ÇÊ¿äÇÑ Á¤º¸¸¦ Á¦°øÇϸç, PESTLE ¿äÀÎÀ» Á¶»çÇÔÀ¸·Î½á ±â¾÷Àº ÀáÀçÀû À§Çè°ú ±âȸ¸¦ ´õ Àß ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ºÐ¼®À» ÅëÇØ ±â¾÷Àº ±ÔÁ¦, ¼ÒºñÀÚ ¼±È£µµ, °æÁ¦ µ¿ÇâÀÇ º¯È­¸¦ ¿¹ÃøÇÏ°í ¼±Á¦ÀûÀÌ°í ´Éµ¿ÀûÀÎ ÀÇ»ç°áÁ¤À» ³»¸± Áغñ¸¦ ÇÒ ¼ö ÀÖ½À´Ï´Ù.

½ÃÀå Á¡À¯À² ºÐ¼® ¸¶¿ì½º ¸ðµ¨ ½ÃÀå¿¡¼­ÀÇ °æÀï »óȲ ÆÄ¾Ç

¸¶¿ì½º ¸ðµ¨ ½ÃÀåÀÇ »ó¼¼ÇÑ ½ÃÀå Á¡À¯À² ºÐ¼®À» ÅëÇØ °ø±Þ¾÷üÀÇ ¼º°ú¸¦ Á¾ÇÕÀûÀ¸·Î Æò°¡ÇÒ ¼ö ÀÖ½À´Ï´Ù. ±â¾÷Àº ¼öÀÍ, °í°´ ±â¹Ý, ¼ºÀå·ü°ú °°Àº ÁÖ¿ä ÁöÇ¥¸¦ ºñ±³ÇÏ¿© °æÀïÀû À§Ä¡¸¦ ÆÄ¾ÇÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ ºÐ¼®Àº ½ÃÀåÀÇ ÁýÁßÈ­, ´ÜÆíÈ­ ¹× ÅëÇÕ Ãß¼¼¸¦ ÆÄ¾ÇÇÒ ¼ö ÀÖÀ¸¸ç, °ø±Þ¾÷ü´Â Ä¡¿­ÇÑ °æÀï ¼Ó¿¡¼­ ÀÚ½ÅÀÇ ÀÔÁö¸¦ °­È­ÇÒ ¼ö ÀÖ´Â Àü·«Àû ÀÇ»ç°áÁ¤À» ³»¸®´Â µ¥ ÇÊ¿äÇÑ ÀλçÀÌÆ®¸¦ ¾òÀ» ¼ö ÀÖ½À´Ï´Ù.

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º : ¸¶¿ì½º ¸ðµ¨ ½ÃÀå¿¡¼­ÀÇ º¥´õ ¼º°ú Æò°¡

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º´Â ¸¶¿ì½º ¸ðµ¨ ½ÃÀå¿¡¼­ º¥´õ¸¦ Æò°¡ÇÏ´Â Áß¿äÇÑ µµ±¸ÀÔ´Ï´Ù. ÀÌ ¸ÅÆ®¸¯½º¸¦ ÅëÇØ ºñÁî´Ï½º Á¶Á÷Àº º¥´õÀÇ ºñÁî´Ï½º Àü·«°ú Á¦Ç° ¸¸Á·µµ¸¦ ±â¹ÝÀ¸·Î Æò°¡ÇÏ¿© ¸ñÇ¥¿¡ ºÎÇÕÇÏ´Â Á¤º¸¿¡ ÀÔ°¢ÇÑ ÀÇ»ç°áÁ¤À» ³»¸± ¼ö ÀÖÀ¸¸ç, 4°³ÀÇ »çºÐ¸éÀ¸·Î º¥´õ¸¦ ¸íÈ®Çϰí Á¤È®ÇÏ°Ô ¼¼ºÐÈ­ÇÏ¿© Àü·« ¸ñÇ¥¿¡ °¡Àå ÀûÇÕÇÑ ÆÄÆ®³Ê¿Í ¼Ö·ç¼ÇÀ» ½Äº°ÇÒ ¼ö ÀÖ½À´Ï´Ù. Àü·« ¸ñÇ¥¿¡ °¡Àå ÀûÇÕÇÑ ÆÄÆ®³Ê¿Í ¼Ö·ç¼ÇÀ» ½Äº°ÇÒ ¼ö ÀÖ½À´Ï´Ù.

Àü·« ºÐ¼® ¹× Ãßõ ¸¶¿ì½º ¸ðµ¨ ½ÃÀå¿¡¼­ ¼º°øÀÇ ±æ ã±â

¸¶¿ì½º ¸ðµ¨ ½ÃÀå Àü·« ºÐ¼®Àº ¼¼°è ½ÃÀå¿¡¼­ÀÇ ÀÔÁö¸¦ °­È­ÇϰíÀÚ ÇÏ´Â ±â¾÷¿¡°Ô ÇʼöÀûÀÔ´Ï´Ù. ÁÖ¿ä ÀÚ¿ø, ¿ª·® ¹× ¼º°ú ÁöÇ¥¸¦ °ËÅäÇÔÀ¸·Î½á ±â¾÷Àº ¼ºÀå ±âȸ¸¦ ½Äº°ÇÏ°í °³¼±ÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Á¢±Ù ¹æ½ÄÀ» ÅëÇØ °æÀï ȯ°æÀÇ °úÁ¦¸¦ ±Øº¹ÇÏ°í »õ·Î¿î ºñÁî´Ï½º ±âȸ¸¦ Ȱ¿ëÇÏ¿© Àå±âÀûÀÎ ¼º°øÀ» °ÅµÑ ¼ö ÀÖµµ·Ï ÁغñÇÒ ¼ö ÀÖ½À´Ï´Ù.

ÀÌ º¸°í¼­´Â ÁÖ¿ä °ü½É ºÐ¾ß¸¦ Æ÷°ýÇÏ´Â ½ÃÀå¿¡ ´ëÇÑ Á¾ÇÕÀûÀÎ ºÐ¼®À» Á¦°øÇÕ´Ï´Ù.

1. ½ÃÀå ħÅõµµ : ÇöÀç ½ÃÀå ȯ°æÀÇ »ó¼¼ÇÑ °ËÅä, ÁÖ¿ä ±â¾÷ÀÇ ±¤¹üÀ§ÇÑ µ¥ÀÌÅÍ, ½ÃÀå µµ´Þ ¹üÀ§ ¹× Àü¹ÝÀûÀÎ ¿µÇâ·Â Æò°¡.

2. ½ÃÀå °³Ã´µµ : ½ÅÈï ½ÃÀå¿¡¼­ÀÇ ¼ºÀå ±âȸ¸¦ ÆÄ¾ÇÇϰí, ±âÁ¸ ºÐ¾ßÀÇ È®Àå °¡´É¼ºÀ» Æò°¡Çϸç, ¹Ì·¡ ¼ºÀåÀ» À§ÇÑ Àü·«Àû ·Îµå¸ÊÀ» Á¦°øÇÕ´Ï´Ù.

3. ½ÃÀå ´Ù°¢È­ : ÃÖ±Ù Á¦Ç° Ãâ½Ã, ¹Ì°³Ã´ Áö¿ª, ¾÷°èÀÇ ÁÖ¿ä ¹ßÀü, ½ÃÀåÀ» Çü¼ºÇÏ´Â Àü·«Àû ÅõÀÚ¸¦ ºÐ¼®ÇÕ´Ï´Ù.

4. °æÀï Æò°¡ ¹× Á¤º¸ : °æÀï »óȲÀ» öÀúÈ÷ ºÐ¼®ÇÏ¿© ½ÃÀå Á¡À¯À², »ç¾÷ Àü·«, Á¦Ç° Æ÷Æ®Æú¸®¿À, ÀÎÁõ, ±ÔÁ¦ ´ç±¹ÀÇ ½ÂÀÎ, ƯÇã µ¿Çâ, ÁÖ¿ä ±â¾÷ÀÇ ±â¼ú ¹ßÀü µîÀ» °ËÅäÇÕ´Ï´Ù.

5. Á¦Ç° °³¹ß ¹× Çõ½Å : ÇâÈÄ ½ÃÀå ¼ºÀåÀ» ÃËÁøÇÒ °ÍÀ¸·Î ¿¹»óµÇ´Â ÷´Ü ±â¼ú, ¿¬±¸ °³¹ß Ȱµ¿ ¹× Á¦Ç° Çõ½ÅÀ» °­Á¶ÇÕ´Ï´Ù.

ÀÌÇØ°ü°èÀÚµéÀÌ ÃæºÐÇÑ Á¤º¸¸¦ ¹ÙÅÁÀ¸·Î ÀÇ»ç°áÁ¤À» ³»¸± ¼ö ÀÖµµ·Ï ´ÙÀ½°ú °°Àº Áß¿äÇÑ Áú¹®¿¡ ´ëÇÑ ´äº¯µµ Á¦°øÇÕ´Ï´Ù.

1. ÇöÀç ½ÃÀå ±Ô¸ð¿Í ÇâÈÄ ¼ºÀå Àü¸ÁÀº?

2. ÃÖ°íÀÇ ÅõÀÚ ±âȸ¸¦ Á¦°øÇÏ´Â Á¦Ç°, ºÎ¹®, Áö¿ªÀº ¾îµðÀΰ¡?

3. ½ÃÀåÀ» Çü¼ºÇÏ´Â ÁÖ¿ä ±â¼ú µ¿Çâ°ú ±ÔÁ¦ÀÇ ¿µÇâÀº?

4. ÁÖ¿ä º¥´õÀÇ ½ÃÀå Á¡À¯À²°ú °æÀï Æ÷Áö¼ÇÀº?

5. º¥´õÀÇ ½ÃÀå ÁøÀÔ ¹× ö¼ö Àü·«ÀÇ ¿øµ¿·ÂÀÌ µÇ´Â ¼öÀÍ¿ø°ú Àü·«Àû ±âȸ´Â ¹«¾ùÀΰ¡?

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå Á¶»ç ¹æ¹ý

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå ½ÃÀå °³¿ä

Á¦5Àå ½ÃÀå ÀλçÀÌÆ®

  • ½ÃÀå ¿ªÇÐ
    • ¼ºÀå ÃËÁø¿äÀÎ
      • ¾à¹° ½ÃÇèÀ̳ª ¸é¿ªÁúȯ Á¶»çÀÇ ¸¶¿ì½º ¸ðµ¨ ÀÌ¿ë È®´ë
      • ÅõÀÚ¿Í Á¶¼º±Ý Áõ°¡¿Í ÀǾàǰ ¿¬±¸°³¹ß Ȱµ¿ ±ÞÁõ
    • ¼ºÀå ¾ïÁ¦¿äÀÎ
      • ¸¶¿ì½º ¸ðµ¨ °³¹ß¿¡ µû¸¥ °íºñ¿ë
    • ±âȸ
      • ¸¶¿ì½º ¸ðµ¨¸µ¿¡¼­ AI¿Í MLÀÇ »õ·Î¿î ±¸Çö
      • ¸¶¿ì½º ¸ðµ¨¸µ¿¡¼­ CRISPR-Cas9 ±â¼úÀÇ µîÀå
    • °úÁ¦
      • Á¶»ç¿¡¼­ µ¿¹°ÀÇ À±¸®Àû »ç¿ëÀ» °í·ÁÇÑ ¾ö°ÝÇÑ ±ÔÁ¦¿Í ¹ý·ü
  • ½ÃÀå ¼¼ºÐÈ­ ºÐ¼®
    • À¯Çü : À¯ÀüÀÚ Ä¡·á °á°ú¸¦ Æò°¡Çϱâ À§ÇÑ À¯ÀüÀÚ Á¶ÀÛ ¸¶¿ì½ºÀÇ Á߿伺 »ó½Â
    • ÀÀ¿ë : ÀÓ»ó½ÃÇè Àü¿¡ Ä¡·á È¿°ú¿Í ¾ÈÀü¼º ÇÁ·ÎÆÄÀÏÀ» Á¶»çÇϱâ À§ÇÑ ¸¶¿ì½º ¸ðµ¨ ä¿ë Áõ°¡
  • Porter's Five Forces ºÐ¼®
  • PESTEL ºÐ¼®
    • Á¤Ä¡Àû
    • °æÁ¦
    • »ç±³
    • ±â¼úÀû
    • ¹ý·ü»ó
    • ȯ°æ

Á¦6Àå ¸¶¿ì½º ¸ðµ¨ ½ÃÀå : À¯Çüº°

  • Á¶°ÇÈ­/¼ö¼úÀûÀ¸·Î º¯ÇüµÈ ¸¶¿ì½º
  • À¯ÀüÀÚ Á¶ÀÛ ¸¶¿ì½º
  • ÀâÁ¾/µ¿Çü Á¢ÇÕ ¸¶¿ì½º
  • ±Ù±³°è ¸¶¿ì½º
  • À̱³°è ¸¶¿ì½º

Á¦7Àå ¸¶¿ì½º ¸ðµ¨ ½ÃÀå : ±â¼úº°

  • CRISPR/CAS9
  • ¹è¾ÆÁٱ⼼Æ÷ ÁÖÀÔ
  • ¸¶ÀÌÅ©·ÎÀÎÁ§¼Ç
  • ÇÙÀ̽Ä

Á¦8Àå ¸¶¿ì½º ¸ðµ¨ ½ÃÀå Ä¡·á ºÐ¾ßº°

  • ½ÉÇ÷°üÁúȯ
  • ¸é¿ªÇÐ
  • ´ë»ç¼º Áúȯ
  • ½Å°æÇÐ
  • Á¾¾çÇÐ

Á¦9Àå ¸¶¿ì½º ¸ðµ¨ ½ÃÀå : ¿ëµµº°

  • ÀǾàǰ ¹ß°ß°ú °³¹ß
  • ¸ÂÃãÇü ÀÇ·á
  • Á¶»ç ¾ÖÇø®ÄÉÀ̼Ç

Á¦10Àå ¾Æ¸Þ¸®Ä«ÀÇ ¸¶¿ì½º ¸ðµ¨ ½ÃÀå

  • ¾Æ¸£ÇîÆ¼³ª
  • ºê¶óÁú
  • ij³ª´Ù
  • ¸ß½ÃÄÚ
  • ¹Ì±¹

Á¦11Àå ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ¸¶¿ì½º ¸ðµ¨ ½ÃÀå

  • È£ÁÖ
  • Áß±¹
  • Àεµ
  • Àεµ³×½Ã¾Æ
  • ÀϺ»
  • ¸»·¹À̽þÆ
  • Çʸ®ÇÉ
  • ½Ì°¡Æ÷¸£
  • Çѱ¹
  • ´ë¸¸
  • ű¹
  • º£Æ®³²

Á¦12Àå À¯·´, Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ ¸¶¿ì½º ¸ðµ¨ ½ÃÀå

  • µ§¸¶Å©
  • ÀÌÁýÆ®
  • Çɶõµå
  • ÇÁ¶û½º
  • µ¶ÀÏ
  • À̽º¶ó¿¤
  • ÀÌÅ»¸®¾Æ
  • ³×´ú¶õµå
  • ³ªÀÌÁö¸®¾Æ
  • ³ë¸£¿þÀÌ
  • Æú¶õµå
  • īŸ¸£
  • ·¯½Ã¾Æ
  • »ç¿ìµð¾Æ¶óºñ¾Æ
  • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
  • ½ºÆäÀÎ
  • ½º¿þµ§
  • ½ºÀ§½º
  • ÅÍŰ
  • ¾Æ¶ø¿¡¹Ì¸®Æ®
  • ¿µ±¹

Á¦13Àå °æÀï ±¸µµ

  • ½ÃÀå Á¡À¯À² ºÐ¼® 2023
  • FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º, 2023
  • °æÀï ½Ã³ª¸®¿À ºÐ¼®
    • BiocytogenÀÌ RenMice ½Ã¸®Á Á¤½ÄÀ¸·Î ¹ß¸Å
    • NeoMab ¼Ò°³ : GemPharmatechÀÇ Çõ½ÅÀûÀÎ Ç×ü À¯ÀüÀÚ Àΰ£È­ ¸¶¿ì½º ¸ðµ¨
    • A Mouse That Roars : Áß±¹ °úÇÐÀÚµéÀÌ ¿ÏÀüÈ÷ ÀçÇÁ·Î±×·¡¹ÖµÈ À¯ÀüÀÚ¸¦ °¡Áø ÃÖÃÊÀÇ Æ÷À¯·ù¸¦ Á¦ÀÛ
    • UCLA ¿¬±¸Áø, ÇåÆÃÅϺ´ÀÇ Ã¹ Àΰ£ °Ô³ð ÇüÁúÀüȯ ¸¶¿ì½º ¸ðµ¨ °³¹ß
  • Àü·« ºÐ¼®°ú Á¦¾È

±â¾÷ ¸®½ºÆ®

  • Applied StemCell, Inc.
  • Aragen Life Sciences Ltd.
  • Biocytogen Boston Corporation
  • Charles River Laboratories International, Inc.
  • CompareNetworks, Inc.
  • Creative Biolabs.
  • Crown Bioscience by JSR Life Sciences, LLC
  • Cyagen US Inc. by PolyGene AG
  • Envigo by Inotiv, Inc.
  • GenOway
  • Harbour BioMed
  • Horizon Discovery Ltd. by PerkinElmer, Inc.
  • inGenious Targeting Laboratory, Inc.
  • ITR Laboratories Canada
  • Janvier Labs
  • Marshall BioResources
  • MD Biosciences
  • Mirimus, Inc.
  • Oncodesign, SA
  • Ozgene Pty Ltd.
  • PhoenixBio Co., Ltd.
  • Shanghai Model Organisms Center, Inc.
  • Taconic Biosciences, Inc.
  • The Jackson Laboratory
  • TransCure bioServices
  • Translational Drug Development, LLC
  • Transnetyx, Inc.
  • Urosphere SAS
  • Vivo Bio Tech Ltd.
  • XenOPAT SL by Bellvitge Biomedical Research Institute
ksm 25.01.02

The Mice Model Market was valued at USD 1.49 billion in 2023, expected to reach USD 1.61 billion in 2024, and is projected to grow at a CAGR of 8.34%, to USD 2.61 billion by 2030.

The mice model market encompasses the use of genetically engineered mice in biomedical research, offering a profound scope as an essential tool for understanding human diseases, drug development, and therapeutic testing. These models are pivotal due to their genetic similarities with humans, facilitating insights into cancer, cardiovascular diseases, metabolic disorders, and more. The necessity of mice models is underscored by their ability to model human disease phenotypes, thus becoming invaluable in translational and preclinical research. Application-wise, they are employed across pharmaceuticals, biotechnology, and academic research institutions, with end-user scope spanning drug discovery, toxicology, and genetic research. Growth in this market is driven by increased government funding for genomic research, rising demand for personalized medicine, and advancements in CRISPR and other genetic engineering technologies. The surge in chronic disease prevalence also bolsters the need for efficient animal models. However, ethical concerns regarding animal testing, along with stringent regulatory frameworks, present significant challenges. Additionally, the complexity involved in developing genetically engineered models and the high cost of maintenance can hinder market expansion. Opportunities lie in developing more sophisticated humanized mice models and enhancing imaging and surveillance technologies to gather more precise data. Embracing open-access platforms for data sharing could foster broader collaborative research and accelerate advancements. Innovations in non-invasive imaging techniques and digital pathology are potent areas for research and development. The nature of the mice model market is highly dynamic and competitive, with continuous emphasis on innovations that enhance model accuracy and reduce ethical concerns. For businesses, tapping into emerging trends like AI-driven data analysis and expanding into untapped regions with growing clinical research infrastructure may yield substantial growth. Overall, while the market faces challenges, the continual demand for efficient research models offers robust growth potential.

KEY MARKET STATISTICS
Base Year [2023] USD 1.49 billion
Estimated Year [2024] USD 1.61 billion
Forecast Year [2030] USD 2.61 billion
CAGR (%) 8.34%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Mice Model Market

The Mice Model Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Escalating use of mice models for drug testing and research of immune disease
    • Rising investments and grants coupled with surging pharmaceutical R&D activities
  • Market Restraints
    • High costs associated with development of mice models
  • Market Opportunities
    • Emerging implementation of AI and ML in mice modeling
    • Advent of CRISPR-Cas9 technology in mice modeling
  • Market Challenges
    • Stringent regulations and laws considering the ethical use of animals in research

Porter's Five Forces: A Strategic Tool for Navigating the Mice Model Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Mice Model Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Mice Model Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Mice Model Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Mice Model Market

A detailed market share analysis in the Mice Model Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Mice Model Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Mice Model Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Mice Model Market

A strategic analysis of the Mice Model Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Mice Model Market, highlighting leading vendors and their innovative profiles. These include Applied StemCell, Inc., Aragen Life Sciences Ltd., Biocytogen Boston Corporation, Charles River Laboratories International, Inc., CompareNetworks, Inc., Creative Biolabs., Crown Bioscience by JSR Life Sciences, LLC, Cyagen US Inc. by PolyGene AG, Envigo by Inotiv, Inc., GenOway, Harbour BioMed, Horizon Discovery Ltd. by PerkinElmer, Inc., inGenious Targeting Laboratory, Inc., ITR Laboratories Canada, Janvier Labs, Marshall BioResources, MD Biosciences, Mirimus, Inc., Oncodesign, SA, Ozgene Pty Ltd., PhoenixBio Co., Ltd., Shanghai Model Organisms Center, Inc., Taconic Biosciences, Inc., The Jackson Laboratory, TransCure bioServices, Translational Drug Development, LLC, Transnetyx, Inc., Urosphere SAS, Vivo Bio Tech Ltd., and XenOPAT SL by Bellvitge Biomedical Research Institute.

Market Segmentation & Coverage

This research report categorizes the Mice Model Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across Conditioned/Surgically Modified Mice, Genetically Engineered Mice, Hybrid/Congenic Mice, Inbred Mice, and Outbred Mice.
  • Based on Technology, market is studied across CRISPR/CAS9, Embryonic Stem Cell Injection, Microinjection, and Nuclear Transfer.
  • Based on Therapeutic Area, market is studied across Cardiovascular Diseases, Immunology, Metabolic Diseases, Neurology, and Oncology.
  • Based on Application, market is studied across Drug Discovery & Development, Personalized Medicine, and Research Application.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Escalating use of mice models for drug testing and research of immune disease
      • 5.1.1.2. Rising investments and grants coupled with surging pharmaceutical R&D activities
    • 5.1.2. Restraints
      • 5.1.2.1. High costs associated with development of mice models
    • 5.1.3. Opportunities
      • 5.1.3.1. Emerging implementation of AI and ML in mice modeling
      • 5.1.3.2. Advent of CRISPR-Cas9 technology in mice modeling
    • 5.1.4. Challenges
      • 5.1.4.1. Stringent regulations and laws considering the ethical use of animals in research
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Type: Growing significance of genetically engineered mice for evaluating gene therapy outcomes
    • 5.2.2. Application: Rising adoption of mice models to explore therapeutic efficacy and safety profiles before clinical trials
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Mice Model Market, by Type

  • 6.1. Introduction
  • 6.2. Conditioned/Surgically Modified Mice
  • 6.3. Genetically Engineered Mice
  • 6.4. Hybrid/Congenic Mice
  • 6.5. Inbred Mice
  • 6.6. Outbred Mice

7. Mice Model Market, by Technology

  • 7.1. Introduction
  • 7.2. CRISPR/CAS9
  • 7.3. Embryonic Stem Cell Injection
  • 7.4. Microinjection
  • 7.5. Nuclear Transfer

8. Mice Model Market, by Therapeutic Area

  • 8.1. Introduction
  • 8.2. Cardiovascular Diseases
  • 8.3. Immunology
  • 8.4. Metabolic Diseases
  • 8.5. Neurology
  • 8.6. Oncology

9. Mice Model Market, by Application

  • 9.1. Introduction
  • 9.2. Drug Discovery & Development
  • 9.3. Personalized Medicine
  • 9.4. Research Application

10. Americas Mice Model Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Mice Model Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Mice Model Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. Biocytogen Officially Launches RenMice Series
    • 13.3.2. Introducing NeoMab: GemPharmatech's Innovative Antibody Gene Humanized Mouse Model
    • 13.3.3. A Mouse That Roars: Chinese Scientists Create The First Mammal With Fully Reprogrammed Genes
    • 13.3.4. UCLA Researchers Develop First Human Genomic Transgenic Mouse Model Of Huntington's Disease
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Applied StemCell, Inc.
  • 2. Aragen Life Sciences Ltd.
  • 3. Biocytogen Boston Corporation
  • 4. Charles River Laboratories International, Inc.
  • 5. CompareNetworks, Inc.
  • 6. Creative Biolabs.
  • 7. Crown Bioscience by JSR Life Sciences, LLC
  • 8. Cyagen US Inc. by PolyGene AG
  • 9. Envigo by Inotiv, Inc.
  • 10. GenOway
  • 11. Harbour BioMed
  • 12. Horizon Discovery Ltd. by PerkinElmer, Inc.
  • 13. inGenious Targeting Laboratory, Inc.
  • 14. ITR Laboratories Canada
  • 15. Janvier Labs
  • 16. Marshall BioResources
  • 17. MD Biosciences
  • 18. Mirimus, Inc.
  • 19. Oncodesign, SA
  • 20. Ozgene Pty Ltd.
  • 21. PhoenixBio Co., Ltd.
  • 22. Shanghai Model Organisms Center, Inc.
  • 23. Taconic Biosciences, Inc.
  • 24. The Jackson Laboratory
  • 25. TransCure bioServices
  • 26. Translational Drug Development, LLC
  • 27. Transnetyx, Inc.
  • 28. Urosphere SAS
  • 29. Vivo Bio Tech Ltd.
  • 30. XenOPAT SL by Bellvitge Biomedical Research Institute
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦